Overview

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
To determine safety and effectiveness of low-dose therapeutic AEGR-733 +/- atorvastatin, ezetimibe or fenofibrate (compared to placebo) on liver fat accumulation measured by Magnetic Resonance Spectroscopy
Phase:
Phase 2
Details
Lead Sponsor:
Aegerion Pharmaceuticals, Inc.
Treatments:
Atorvastatin
Atorvastatin Calcium
Ezetimibe
Fenofibrate